Poseida announces CEO transition; Kristin Yarema to become CEO, Mark Gergen to become Executive Chairman

Poseida Therapeutics, Inc.

Kristin Yarema, currently President, Cell Therapy, appointed President and CEO effective January 1, 2024.
Mark Gergen, current President and CEO, will become Executive Chairman of the Board on the same date.
Amended employment agreements to be entered with Dr. Yarema and Mr. Gergen prior to effective date.
No material transactions or family relationships disclosed between Dr. Yarema and the company.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Mark Gergen

Executive Chairman

Poseida Therapeutics, Inc.

Effective: 2024-01-01
Filed: October 10, 2023, 7:59 PM ET

The Board also appointed Mark Gergen, the Company’s current President and Chief Executive Officer, as Executive Chairman of the Board.

Role change

Kristin Yarema

President and Chief Executive Officer

Poseida Therapeutics, Inc.

Effective: 2024-01-01
Filed: October 10, 2023, 7:59 PM ET

approved a leadership transition appointing Kristin Yarema, Ph.D., as President and Chief Executive Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Gergen was appointed as Executive Chairman at Poseida Therapeutics, Inc..

Action: appointed
Role: Executive Chairman

Exact text from the filing

The Board also appointed Mark Gergen, the Company’s current President and Chief Executive Officer, as Executive Chairman of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Kristin Yarema was appointed as President and Chief Executive Officer at Poseida Therapeutics, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

approved a leadership transition appointing Kristin Yarema, Ph.D., as President and Chief Executive Officer of the Company.

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-23-252990

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.